Fusion Antibodies
Fusion Antibodies is a contract research organisation specialising in preclinical antibody discovery, engineering and supply for pharmaceutical and diagnostic clients.
Services span antigen expression, antibody generation, humanisation, affinity maturation, developability optimisation, and stable cell line development.
The company serves both therapeutic and diagnostic antibody programmes, with clients including eight of the top ten global pharmaceutical companies by revenue.
Fifteen client projects have advanced to clinical stage trials.
Latest News
Fusion Antibodies Shares Fall 41% as AGM Update Flags Weak First Half
Fusion Antibodies shares fell more than 41% to 5.75p after its AGM update said difficult healthcare market conditions had weighed on first-half performance. The company said commercial agreements for its OptiMAL platform, launched in December 2025, will take time to secure.
Fusion Antibodies Receives Notice of Acceptance for Australian Patent
Fusion Antibodies has received a notice of acceptance from IP Australia for its patent application covering two families of antibodies and methods for designing antibody libraries, complementing its OptiMAL antibody discovery platform. The company is progressing equivalent patent applications in Europe and China, with the Australian patent expected to grant after a three-month gazetting period.